Gadoxetate Acid-Enhanced MRI for HCC: A Review
Author Information
Author(s): Chanyaputhipong Jendana, Low Su-Chong Albert, Chow Pierce K. H.
Primary Institution: Singapore General Hospital
Hypothesis
Gadoxetate acid-enhanced MRI improves the detection and characterization of hepatocellular carcinoma (HCC) compared to other imaging modalities.
Conclusion
Gadoxetate acid-enhanced MRI is superior to unenhanced MRI and CT in detecting and characterizing liver lesions, particularly small HCCs.
Supporting Evidence
- Gadoxetate acid-enhanced MRI has shown superior sensitivity in detecting small HCCs compared to traditional imaging methods.
- Studies indicate that gadoxetate acid can improve liver-to-lesion contrast, aiding in the diagnosis of liver lesions.
- Clinical trials have demonstrated the safety and tolerability of gadoxetate acid in patients undergoing MRI.
Takeaway
This study shows that a special type of MRI using a contrast agent called gadoxetate acid helps doctors find liver cancer better than regular scans.
Methodology
The study reviewed existing literature on gadoxetate acid-enhanced MRI and its effectiveness in detecting HCC.
Potential Biases
Potential bias due to the reliance on existing studies and the lack of human studies confirming safety in patients with renal impairment.
Limitations
The study primarily focused on larger tumors and may not fully represent the performance in smaller lesions or in patients with advanced liver disease.
Participant Demographics
The study included patients with varying degrees of liver disease, primarily focusing on those with cirrhosis.
Statistical Information
P-Value
0.0001
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website